See Important Safety Information, including Boxed Warning. Learn about Teva's Shared Solutions® for AUSTEDO XR® (deutetrabenazine) extended-release tablets.

7. Nov. 2025 · The data presented at a significant neuroscience congress demonstrate the effectiveness of AUSTEDO and AUSTEDO XR in reducing the severity of involuntary movements …

3. Juni 2024 · Additionally, Austedo XR can be used alongside CYP3A4/5 inducers or inhibitors with no dose restrictions, so patients can continue treating their mental health conditions, and …

19. Apr. 2024 · AUSTEDO XR and AUSTEDO are the first vesicular monoamine transporter 2 (VMAT2) inhibitors approved by the U.S. Food and Drug Administration in adults for the …

20. Sept. 2025 · Patients taking AUSTEDO XR reported increased social and emotional well-being as a result of movement reduction, and high overall satisfaction with AUSTEDO XR. The data …

29. Mai 2024 · U.S. FDA approves new one pill, once-daily AUSTEDO XR tablets (30, 36, 42, 48 mg/day) AUSTEDO XR offers more flexibility with the most once-daily doses of any vesicular …

2. Nov. 2023 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and …

1. Aug. 2025 · References Austedo/Austedo XR (deutetrabenazine) [prescribing information]. Parsippany, NJ: Teva Neuroscience, Inc; February 2025. Indirect tolerability compar al. Long …

26. Feb. 2025 · For use in tardive dyskinesia, Austedo or Austedo XR must be prescribed by or in consultation with a neurologist or psychiatrist. Documented diagnosis of tardive dyskinesia …

12. Nov. 2024 · The survey examined patient-reported ease of use, effectiveness, and satisfaction. In this interim analysis of data from 131 respondents, results revealed that 87% …